Skip to main content
Premium Trial:

Request an Annual Quote

NCI Awards SBIR Grant to Structural Bioinformatics

Premium

SAN DIEGO--The US National Cancer Institute has awarded a $100,000 Small Business Innovation Research grant to Structural Bioinformatics to support its work developing nonpeptide small-molecule antagonists targeting the HER2 breast cancer-related gene. The government funding will enable Structural Bioinformatics' scientists to apply the company's proprietary protein modeling and dynamic pharmacophore-based searching of existing and virtual combinatorial libraries to identify and synthesize putative small-molecule HER2 antagonists. The company said it will first use its patented and proprietary algorithms to model the dynamic surface of the target protein, and then to extract 3D-pharmacophore structural information used to computationally prescreen large-scale small-molecule compound libraries for likely drug activity. Structural Bioinformatics has already successfully applied this technology to six clinically important protein targets on behalf of three corporate pharmaceutical collaborators in the past 18 months, in each case generating series of antagonists for each target in the viral protease, protein kinase, hormone, and apoptosis areas.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.